Browse News
Filter News
Found 50,578 articles
-
Cognate BioServices Announces Major Expansion of Manufacturing Facilities in US and Europe
1/14/2021
Cognate BioServices, Inc., the premier commercial-ready, global CDMO in the Cell and Gene Therapy industry, announced today its plans to expand cell and gene therapy manufacturing capacity, laboratory space, warehousing capabilities, and increase office support at its facilities in the United States and Europe .
-
Global Contraceptives Market: 3 notable trends outlining the industry forecast through 2025
1/14/2021
The exponentially increasing popularity of birth control measures to control the risk of unintended pregnancies is amplifying the demand for safe and reliable contraceptive solutions.
-
Sana Biotechnology has filed with the U.S. Securities and Exchange Commission to raise up to $150 million in an initial public offering to help support the company’s cell-based therapy discovery and development operations.
-
While Sutro’s technological platform opens multiple therapeutic doors, the company’s singular focus on homogeneous molecules is a key part of its competitive strategy.
-
In order to play the “cat and mouse” game with poise, here’s a breakdown of the steps you’ll need to negotiate properly.
-
DBV announced official restructuring plan for keeping the company afloat.
-
Adverum Biotechnologies Announces New GMP Gene Therapy Manufacturing Facility
1/7/2021
-- 174,000-square-foot commercial GMP facility in Durham, NC for the manufacturing of ADVM-022, an intravitreal gene therapy in development for wet AMD and DME -- -- Multiple production suites with total capacity of 4000L, with further expansion opportunities -- -- Adverum to invest over $80M to be production-ready by end of 2023 and create more than 200 life sciences jobs; Company to receive state and local incentives of up to $9M --
-
Top 12 Biotech Companies Hiring Now
1/5/2021
The new year is here and the biotech job market is hot! A new year, a new you, a new job? -
Artiva Biotherapeutics Announces Appointment of Dr. Fred Aslan as President and CEO
1/5/2021
Artiva Biotherapeutics, Inc., an oncology company focused on developing and commercializing primary allogeneic natural killer (NK) cell therapies to treat cancer, announced today the appointment of Fred Aslan, M.D., as President and Chief Executive Officer
-
Simply staying organized will help you make sure you never miss a beat. Here are a few small steps that’ll make a big difference.
-
Over the course of 2020, the biopharmaceutical industry came together to rapidly address the global COVID-19 crisis. Despite that spirit of comradery and partnership, there were still a few incidents that caused some arched eyebrows, gasps of astonishment and even fits of anger.
-
Virginia Bio Will Direct New “Virginia Bio-Connect” Statewide Consortium to Strengthen Competitiveness of Virginia’s Life Science Ecosystem
12/23/2020
Governor Northam and the Virginia Biotechnology Association announced today that GO Virginia has approved a competitive grant request to help fund Virginia Bio-Connect, a $3.2 million Statewide industry cluster scale up initiative. The project, directed by the Virginia Biotechnology Association, is a multi-regional collaboration designed to increase connectivity and awareness of the existing programs, resources, and commun
-
Myovant's oral Orgovyx beat out Abbvie's injectable Lupron in achieving medical castration levels in patients.
-
Novartis is acquiring Cambridge, Massachusetts-based Cadent Therapeutics for $210 million up front and a possible $560 million in milestone payments.
-
Biocom Institute Launches Largest Diversity, Equity and Inclusion Report in California’s Life Science Industry
12/17/2020
Biocom Institute, a 501(c)(3) non-profit that supports life science innovation by strengthening the workforce and leaders of tomorrow, launched its first biennial report, “ Diversity, Equity and Inclusion in California’s Life Science Industry .” With more than 350 respondents, this report repre
-
A little more than one year after Gilead Sciences and Galapagos NV announced intentions to seek regulatory approval for Jyseleca (filgotinib) as a treatment for rheumatoid arthritis, the companies have pulled the plug on that goal.
-
All eyes are turning to Moderna, which has a meeting with the U.S. Food and Drug Administration (FDA)’s Vaccines and Related Biological Products Advisory Committee on Thursday, December 17. The agency released the data application today.
-
If you want to be a successful leader in the biotech field, here are a few tried and true tips.
-
Cannara Biotech Inc. (CSE: LOVE) announces Year-End and Q4 2020 Results
12/15/2020
Cannara Biotech Inc. ("Cannara") (CSE: LOVE) (OTCQB: LOVFF) (FRA: 8CB) today announced the financial results for the three-month period and year ended August 31, 2020.
-
FACIT fuels promising made-in-Ontario breast cancer therapeutic and medtech innovations through Prospects Oncology Fund
12/10/2020
FACIT, Ontario's oncology commercialization venture firm, announced the newest recipients of Ontario First seed capital through the latest round of its Prospects Oncology Fund: Dr. Rebecca Laposa of the University of Toronto, as well as London-based start-up Multi-Magnetics Inc., scientifically led by Dr. Jeffrey Carson and spun out of the Lawson Health Research Institute.